Aberrant signaling pathways in medulloblastomas: A stem cell connection;Vias de sinalização aberrantes no meduloblastoma: Uma conexão com célula-tronco

Arquivos de Neuro-Psiquiatria

Volumn 68, Issue 6, 2010, Pages 947-952

  Rodini, Carolina Oliveira ^a   Suzuki, Daniela Emi ^a   Nakahata, Adriana Miti ^a   Pereira, Márcia Cristina Leite ^a   Janjoppi, Luciana ^a   Toledo, Silvia Regina Caminada ^a   Okamoto, Oswaldo Keith ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biological therapy; Medulloblastoma; Neurobiology; Signal transduction; Stem cells; Transforming growth factor beta

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CD133 ANTIGEN; HERMES ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNE DISEASE; BRAIN CANCER; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CHILDHOOD CANCER; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; GENETICS; HUMAN; MEDULLOBLASTOMA; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; PARKINSON DISEASE; PURKINJE CELL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 79251591067     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2010000600021     Document Type: Review

References (60)

1. Rood BR, MacDonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Sem Oncol 2004;31:666-675.
2. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathological and molecular markers of prognosis: toward a new disease risk stratification for medulloblastoma. J Clin Oncol 2004;22:984-993.
3. Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 2007;4:295-304.
4. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Ann Rev Pathol Mech Dis 2008;3:341-365.
5. Carlotti Jr CG, Smith C, Rutka JT. The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg Rev 2008; 31:359-369.
6. Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics 2009;6:570-586.
7. Gilbertson R. Paediatric embryonic brain tumours: biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002;38: 675-685.
8. Nicholson J, Wickramasinghe C, Ross F, Crolla J, Ellison D. Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridization and fluorescence in situ hybridization. Mol Pathol 2000; 53:313-319.
9. Steichen-Gersdorf E, Baumgartner M, Kreczy A, Maier H, Fink FM. Deletion mapping on chromosome 17p in medulloblastoma. Br J Cancer 1997;76: 1284-1287.
10. McCabe MG, Ichimura K,. Pearson DM, et al. Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes Chromo Cancer 2009;48:121-131.
11. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol 2008;26: 2821-2827.
12. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66:7445-7452.
13. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006;24:1924-1931.
14. Nakano I, Kornblum HI. Brain tumor stem cells. Pediatr Res 2006;9:54-58.
15. Sigh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nat Publis Group 2004;432:396-401.
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3: 730-737.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988.
18. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-7021.
19. Sigh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828.
20. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
21. Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005;11:17-22.
22. Fogarty MP, Kessler JD, Wechsler-Reya RJ. Morphing into cancer: the role of developmental signaling pathways in brain tumor formation. J Neurobiol 2005;64:458-475.
23. Knoepfler PS, Kenney AM. Neural precursor cycling at sonic speed: N-Myc pedals, GSK-3 brakes. Cell Cycle 2006;5:47-52.
24. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors, Ann Rev Neurosci 2001;24:385-428.
25. Dahmane N, Ruiz i Altaba A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 1999;126:3089-3100.
26. Weiner HL, Bakst R, Hurlbert MS, et al. Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1. Cancer Res 2002;62:6385-6389.
27. Ciemerych MA, Kenney AM, Sicinska E, et al. Development of mice expressing a single D-type cyclin. Genes Dev 2002;16:3277-3289.
28. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors, Development 2003;130:15-28.
29. Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 2002;16:2699-26712.
30. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromo Cancer 2000;27:44-51.
31. Chidambaram A, Goldstein AM, Gailani MR, et al. Mutations in the human homologue of the Drosophila patched gene in Caucasian and African-American nevoid basal cell carcinoma syndrome patients. Cancer Res 1996; 56:4599-4601.
32. Fukushima Y, Oka H, Utsuki S, Iwamoto K, Fujii K. Nevoid basal cell carcinoma syndrome with medulloblastoma and meningioma: case report. Neurol Med Chir 2004;44:665-668.
33. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008;14:135-145.
34. Baeza N, Masuoka J, Kleihues P, Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003;22:632-636.
35. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-847.
36. Bottner M, Krieglstein K, Unsicker K. The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions. J Neurochem 2000;75:2227-2240.
37. Unsicker K, Krieglstein K. TGF-betas and their roles in the regulation of neuron survival. Adv Exp Med Biol 2002;513:353-374.
38. Massague J. TGF-beta signal transduction. Ann Rev Biochem 1998;67: 753-791.
39. Aigner L, Bogdahn U. TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res 2008;331:225-241.
40. Massague J, Weis-Garcia F. Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. Cancer Surv 1996;27: 41-64.
41. Golestaneh N, Mishra B. TGF-b, neuronal stem cells and glioblastoma. Oncogene 2005;24:5722-5730.
42. Flanders KC, Ren RF, Lippa CF. Transforming growth factorbetas in neurodegenerative disease. Prog Neurobiol 1998;54:71-85.
43. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1: 169-178.
44. Nichols NR. Glial responses to steroids as markers of brain aging. J Neurobiol 1999;40:585-601.
45. Issazadeh S, Mustafa M, Ljungdahl A, et al. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 1995;40:579-590.
46. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett 1995;193: 129-132.
47. Baker CA, Lu ZY, Zaitsev I, Manuelidis L. Microglial activation varies in different models of Creutzfeldt-Jakob disease. J Virol 1999;73:5089-5097.
48. Iłzecka J, Stelmasiak Z, Dobosz B. Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 2002;20: 239-243.
49. Buckwalter MS, Yamane M, Coleman BS, et al. TGF-1 Inhibits hippocampal neurogenesis. Am J Pathol 2006;169:154-164.
50. Calegari F, Huttner WB. An inhibition of cyclin-dependent kinases that lengthens, but does not arrest, neuroepithelial cell cycle induces premature neurogenesis. J Cell Sci 2003;116:4947-4955.
51. Battista D, Ferrari CC, Gage FH, Pitossi FJ. Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur J Neurosci 2006;23:83-93.
52. Wachs F, Winner B, Couillard-Despres S, et al. Transforming growth factor-A1 is a negative modulator of adult neurogenesis. J Neuropathol Exp Neurol 2006;65:358-370.
53. Isoe S, Naganuma H, Nakano S, et al. Resistance to growth inhibition by transforming growth factor-beta in malignant glioma cells with functional receptors. J Neurosurg 1998;88:529-534.
54. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004;64:7596-7603.
55. Jennings MT, Kaariainen IT, Gold L, Maciunas RJ, Commers PA. TGF beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: evidence in support of an autocrine hypothesis. Hum Pathol 1994;25:464-475.
56. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454.
57. Kjellman C, Olofsson SP, Hansson O, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000;89:251-258.
58. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004;3:430-446.
59. Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003;9:1033-1038.
60. Rios I, Alvarez-Rodriguez R, Marti E, Pons S. Bmp2 antagonizes sonic hedgehog-mediated proliferation of cerebellar granule neurones through Smad5 signalling. Development 2004;131:3159-3168.